Ultra Fine Bubble

ORAL INSULIN

News Release

06/01/2024: NEW! Signed a joint research agreement with Department of Chemistry, Faculty of Medicine, Keio University.

05/17/2024: Notice of Completion of Seed Investment Round

04/22/2024: Statement of wage increase plan for employees

03/25/2024: Signed a consulting agreement with PQE Japan K.K.

Enhancing Lives Worldwide with Ultra-Fine Bubble (UFB) Water

Ultra Fine ^Bubble†1 (UFB) is a bubble of less than 1.0 um in a liquid. Since UFBs are extremely small, Brownian motion is dominant and they do not float in liquids. They also hardly deflate. If not stimulated, UFBs are reported to have a lifespan of several months to a year or more. Furthermore, in viscous liquids, their lifespan is thought to be further extended in accordance with Stokes’ law.

UFB water is by no means magic water. However, we believe that by properly understanding and utilizing the features and characteristics of UFB water, we can contribute to the enrichment of people’s lives.

Our goal is to discover medical applications for UFB water based on the philosophy of “Reducing the Pain and Burden on Patients”.

Ultra Fine Bubble (†1, Ultra Fine Bubble; UFB) is a bubble of less than 1.0 um in a liquid, which was first announced by AIST in 2004 and has been globally established as a technology originating from Japan. Since UFBs are extremely small, Brownian motion is dominant and they do not float in liquids. They also hardly deflate. If not stimulated, UFBs are reported to have a lifespan of several months to a year or more. Furthermore, in viscous liquids, their lifespan is thought to be further extended in accordance with Stokes’ law.

Our goal is to discover medical applications for UFB water based on the philosophy of “Reducing the Pain and Burden on Patients”.

†1 Ultra Fine Bubble: Bubbles less than 1.0 um. It is called “UFB (Ultra Fine Bubble)”. Registered trademark of FBIA (Fine Bubble Industry Association). Our company has obtained permission from the FBIA to use “Ultra Fine Bubble (UFB)”.

SOCIAL ISSUES

There are people who are suffering.

Diabetes stands as one of the most prevalent diseases worldwide. With approximately 530 million patients as of 2021, this number is projected to escalate to 1.3 billion by 2050.

Currently, a diverse array of medications exists for diabetes treatment, including numerous non-injectable options. These include SGLT-2 inhibitors, which lower blood sugar levels by excreting glucose in urine, GLP-1 receptor agonists that mimic the function of GLP-1 hormone to stimulate insulin secretion, and DPP-4 inhibitors, which suppress the enzyme responsible for breaking down incretin hormones like GLP-1. However, these medications presuppose the presence of insulin production within the body.

Nevertheless, there are cases where insulin is minimally or not produced at all within the body. In such instances, insulin administration becomes imperative. Additionally, for optimal blood sugar control, adjunct or switching therapies involving insulin may be necessary. Yet, insulin therapy solely relies on injectable formulations. The development of oral insulin medications would undeniably revolutionize the quality of life for countless diabetes patients.

Under what circumstances is insulin therapy necessary? Diabetes is classified into Type 1, Type 2, diabetes resulting from specific mechanisms or conditions, and gestational diabetes. Type 1 diabetes, characterized by the destruction of pancreatic beta cells, necessitates insulin therapy primarily. In most cases of Type 1 diabetes, individuals are required to administer injections four times a day. Moreover, Type 1 diabetes often manifests during childhood to adolescence, requiring long-term management with insulin formulations. Conversely, Type 2 diabetes patients may also require adjunct or switch therapies involving insulin, depending on their condition.

※ As of 2021, it is estimated that there are 84 million Type 1 diabetes patients worldwide, with this number continuing to rise, projected to double by 2040 (estimated at 100,000 to 140,000 in Japan).

Diabetes stands as one of the most prevalent diseases worldwide. With approximately 530 million patients as of 2021, this number is projected to escalate to 1.3 billion by 2050.

OUR MISSION

Free from daily injections

Injectable insulin has been manufactured and marketed by Novo Nordisk of Denmark for more than 100 years. Various improvements have been made to the way insulin is manufactured, but the method of administration, injection, has not changed. As a result, many diabetics rely on injectable administration and struggle with where to give it every day and every meal, how to store it, and how to dispose of it.

Our goal is to realize oral insulin using UFB water, and to change society so that many diabetes patients can lead richer lives by alleviating their suffering and burden.

Furthermore, we aim to apply and develop DDS drug discovery technology using this UFB water to create oral drugs such as protein drugs, biopharmaceuticals, and antibody drugs.

Our goal is to realize oral insulin using UFB water, and to change society so that many diabetes patients can lead richer lives by alleviating their suffering and burden.

Furthermore, we aim to apply and develop DDS drug discovery technology using this UFB water to create oral drugs such as protein drugs, biopharmaceuticals, and antibody drugs.

TOP MESSAGE

The possibilities for UFB water are endless.

Pharstoma Corporation was established with the aim of using UFB water to benefit society to its fullest potential. We hope to greatly improve the lives of people living in our society.

The first target is to turn an injectable drug into an oral drug, which was previously considered impossible, and this will be achieved by taking advantage of the characteristics of UFB.

First, we make oral insulin pills. For diabetics who need insulin therapy, frequent injections are a heavy burden.

Our primary goal is to develop an oral formulation that can be administered by injection and significantly reduce the pain and burden of diabetic patients.

By the way, used needles for insulin injections are classified as home health care waste. They must be taken home even when injected outside the home. Their disposal must follow the rules of the local government. This is a burden for patients and their families. In addition, there is the risk of infection due to needle-stick accidents by cleaning workers. Eliminate all of these concerns by eliminating the millions of used insulin needles that are injected in each home every day.

This is also linked to SDG Goal 12 “Responsibility to Create, Responsibility to Use”. We aim to reduce home healthcare waste.

TOP MESSAGE

The possibilities for UFB water are endless.

Pharstoma Corporation was established with the aim of using UFB water to benefit society to its fullest potential. We hope to greatly improve the lives of people living in our society.

The first target is to turn an injectable drug into an oral drug, which was previously considered impossible, and this will be achieved by taking advantage of the characteristics of UFB.

First, we make oral insulin pills. For diabetics who need insulin therapy, frequent injections are a heavy burden.

Our primary goal is to develop an oral formulation that can be administered by injection and significantly reduce the pain and burden of diabetic patients.

This is also linked to SDG Goal 12 “Responsibility to Create, Responsibility to Use”. We aim to reduce home healthcare waste.

PEOPLE

Masahiko Kubota

Founder & CEO

Graduated from Keio University, Faculty of Science and Technology

Completed Master’s program in Chemistry, Graduate School of Science and Technology, Keio University

Joined Canon Inc.

Retired after serving as General Manager of the Inkjet Technology Development Center

Over 20 years of R&D work in inkjet printers at Canon Inc.

The discovery and invention of the ink-jet method of generating UFB

Engaged in research and development of UFB water and applied research for 8 years.

Pharstoma Corporation established to explore the possibilities of UFB water

Hideyuki Muto

Founder & Director CFO

Vice President, Creator’s Board, Inc.

B.A. in International Economics, Faculty of Economics, Yokohama National University

Worked in the banking and IT fields, and served as Director and CFO of CHF Corporation before joining the company.

Strong in IT and finance

Mari Kubota

Founder & Director CTO

D., Associate Professor, School of Medicine, Keio University

Graduated from Keio University, Faculty of Science and Technology

Completed Master’s program in Chemistry, Graduate School of Science and Technology, Keio University

Completed Doctoral program in Chemistry, Graduate School of Science and Technology, Keio University

Assistant Professor and Full-time Lecturer, Faculty of Medicine, Keio University before assuming his current position

Adjunct Lecturer, Faculty of Science and Technology, Keio University

Part-time Lecturer, Department of Applied Chemistry, Faculty of Science and Technology, Toyo University

Masato Yasui

Technical Advisor

Professor, Keio University School of Medicine, M.D.

Graduated from Keio University School of Medicine

After serving as a lecturer and assistant professor at Johns Hopkins University School of Medicine in the U.S., became a professor at Keio University School of Medicine

Engaged in research in Life Sciences, Pharmacology and Water Biology

Yoko Matsuzawa

Advisor

Director, Matsuzawa Internal Medicine & Diabetes Clinic
Doctor of Medicine, Certified Specialist, Supervisor, and Council Member of the Japan Diabetes Society
Master’s Degree in Sociology, Graduate School of Social Sciences, Keio University
Bachelor of Medicine, Chiba University
Doctoral Program Graduate, Graduate School of Medicine, Chiba University
Former Vice Chief of the Endocrinology and Diabetes Center, Yokohama Rosai Hospital

Hideki Fujii

Advisor

Professor, Keio University School of Medicine, Ph.D. in Science

Graduated from the Faculty of Science, Hokkaido University

Completed the Doctoral Program in Chemistry, Graduate School of Science, Hokkaido University

After serving as a Research Fellow at the Scripps Research Institute in the United States, a Researcher at the National Institute of Infectious Diseases, an Assistant Professor at Keio University School of Medicine, an Associate Professor at the Graduate School of Medicine, University of the Ryukyus, and a Professor at the Institute of Health Biosciences, the University of Tokushima, currently holds the present position

Engaged in research in immunology, infection immunology, and microbiology

Yasuhiro Bono

Intellectual Property/Contract Patent Office

Position: Director, BONO International Patent Office Patent Attorney (Registration Number: 12738)

Education:

Bachelor of Engineering, School of Science and Engineering, Waseda University
Graduate Studies, School of Science and Engineering, Waseda University

Professional Experience:

Engaged in intellectual property-related work at a major patent office since 1999.
Passed the Patent Attorney Examination in 2002.
Established BONO International Patent Office in 2018.

Koichi Terasaka

Collaborative Research Partner

Professor, Doctor of Engineering, Faculty of Science and Engineering, Keio University
Graduated from Keio University Faculty of Science and Engineering
Keio University Graduate School Master’s Program, Graduate School of Science and Engineering, Department of Applied Chemistry, Completed
Completed doctoral course, Graduate School of Science and Engineering, Department of Applied Chemistry, Keio University
Current position after working as assistant, full-time lecturer, assistant professor, and associate professor at Keio University Faculty of Science and Engineering.
Specialty: Chemical engineering (fine bubble)
Director of Fine Bubble Industry Association
Chairman of the Federation of Fine Bubble Societies

DATA

Global Diabetes Market

Type 1 diabetes market size was valued at US$ 7.59 billion in 2022 and is expected to reach US$ 13.64 billion by 2030, growing at a CAGR of 7.6% over the forecast period 2023-2030.

Source SNS Insider

Date May 2022

Type 1 Diabetes Market Size (2023-2030)

Global Diabetes Drug Market

The global diabetes drugs market size was estimated at USD 66 billion in 2023 and is projected to reach approximately USD 118 billion by 2032, growing at a CAGR of 6.67% during the forecast period 2023-2032.

62 million people in the Americas have diabetes

Diabetes is the direct cause of 284,049 deaths each year

North America has the largest market share during the forecast period

Source PRECEDENCE RESEARCH

Date May 2023

Diabetes Drug Market Size (2022-2032)

Number of Type 1 Diabetes Patients Worldwide

They found that in 2021 there will be approximately 8.4 million T1D patients worldwide, 18% of whom will be under 20 years of age, 64% will be between 20 and 59 years of age, and 19% will be over 60 years of age. In 2021, 500,000 new cases with a median age of onset of 39 years
Type 1 diabetes cases expected to double worldwide between 2021 and 2040

Source Health Day

Date Sep 2022

Number of diabetics worldwide

Worldwide, 529 million people (95% uncertainty interval [UI] 500 – 564) live with diabetes

131 million (1.22-1.39) people will have diabetes in 2050

Source THE LANCET

Date Jun 2023

Projected prevalence of type 1 and type 2 diabetes (2000-2040)

CORPORATE

Company name Pharstoma Inc.

Establishment October 2023

Masahiko Kubota, Representative Director
Director Hideyuki Muto
Director Mari Kubota

Address: 105-6415
1-17-1 Toranomon, Minato-ku, Tokyo
Toranomon Hills Business Tower 15F

Representative phone: 03-6807-5976

Contact us

Name Required
Mail Address Required
Company Name Optional
Zip Code Required
Prefecture Required
Address Required
Tel. Required
Title. Required
Message Required
Privacy Policy Required	I agree to the privacy policy. Click here if you would like to view the contents

News Release

Enhancing Lives Worldwide with Ultra-Fine Bubble (UFB) Water

SOCIAL ISSUES

There are people who are suffering.

OUR MISSION

Free from daily injections

TOP MESSAGE

The possibilities for UFB water are endless.

TOP MESSAGE

The possibilities for UFB water are endless.

PEOPLE

Masahiko Kubota

Founder & CEO

Hideyuki Muto

Founder & Director CFO

Mari Kubota

Founder & Director CTO

Masato Yasui

Technical Advisor

Yoko Matsuzawa

Advisor

Hideki Fujii

Advisor

Yasuhiro Bono

Intellectual Property/Contract Patent Office

Koichi Terasaka

Collaborative Research Partner

DATA

Global Diabetes Market

Global Diabetes Drug Market

Number of Type 1 Diabetes Patients Worldwide

Number of diabetics worldwide

CORPORATE

Contact us

Log in with your credentials

Forgot your details?